The risk of developing bile duct cancer, also known as cholangiocarcinoma, is almost doubled for type 2 diabetics using one of the following diabetes medicines: Januvia (sitagliptin) Janumet (sitagliptin / metformin HCl) Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Qtern (dapagliflozin and saxagliptin) Nesina … [Read more...]
Rhabdomyolysis May Be Linked To A New Class Of Oral Diabetes Medicines
A class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors may be associated with rhabdomyolysis, a side effect which involves severe muscle damage. In more detail, rhabdomyolysis is the breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood. These substances are harmful to the kidney and … [Read more...]
Type 2 Diabetes Drugs Linked to Severe Joint Pain
Health Canada recently warned about the risk of severe, debilitating joint pain as a result of taking type 2 diabetes medications called dipeptidylpeptidase-4 (DPP-4) inhibitors. This DPP-4 inhibitors class of drugs includes the following: Onglyza Kombiglyze XR Nesina Kazano Oseni Glyxambi Janumet (XR) Januvia … [Read more...]